Browse the evidence

Cardiomyocyte lipid aggregation in obesity causes insulin resistance and cardiovascular hypertrophy, reducing overall heart function.

Interventions targeting lipid metabolism may improve heart function in obese patients.

The review emphasizes moving from a binary approach to a quantitative approach in trials regarding glycaemic exposure.

Researchers should consider adopting quantitative measures of glycaemic exposure in future trials to better assess cardiovascular outcomes.

Choosing the optimal diet therapy for a patient with NAFLD is complicated due to the multifactorial nature of the disease.

Practitioners should recognize the complexity in selecting diet therapies for NAFLD patients.

Immobilization rapidly reduces ADP‐stimulated mitochondrial respiration by approximately 20% within 3 days.

Understanding the rapid decline in mitochondrial function can inform rehabilitation strategies post-immobilization.

The greater acute increase in type II muscle fibre satellite cell content at 24 hours post-exercise recovery after training was correlated with an increase in type II muscle fibre capillarization.

Improved capillarization may enhance satellite cell function in older adults after exercise training.

The severity of hypothalamic inflammation and gliosis is related to comorbid conditions such as glucose intolerance and insulin resistance.

Understanding these relationships can help in targeting treatment for obesity-related comorbidities.

Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose.

Clinicians should monitor for gastrointestinal side effects when prescribing maridebart cafraglutide.

In rheumatoid arthritis (RA), improved disease activity was reported with GLP-1 receptor agonists.

GLP-1 receptor agonists may be beneficial for improving disease activity in RA patients.

The restore diet reduced gut microbiome diversity but enhanced the persistence of L. reuteri strain.

Practitioners should note that while diversity may decrease, specific beneficial strains can be enhanced through targeted dietary interventions.

Changes in inflammatory and oxidative stress markers after resistance training are correlated with changes in phase angle.

Monitoring phase angle may provide insights into the effectiveness of resistance training on health markers.

Statins are usually recommended as first-line treatment for dyslipidaemia.

Clinicians should consider statins as the first option for managing dyslipidaemia.

Adverse measures of body composition in individuals of any weight can also confer increased breast cancer risk.

Practitioners should assess body composition in addition to BMI when evaluating breast cancer risk.

Endothelial dysfunction is associated with hypercholesterolemia and obesity.

Understanding endothelial dysfunction can help in the treatment of CVD risk factors.

Prolonged, intense weight-bearing exercise can increase intestinal permeability but effects are transient.

While intense exercise can temporarily affect gut health, these effects are not long-lasting.

Type 2 diabetes mellitus (T2DM) patients are at an increased risk for cardiovascular disease (CVD).

Healthcare providers should be aware of the increased cardiovascular risks in T2DM patients.

SGLT2 inhibitors reduce cardiovascular morbidity and mortality in patients with type 2 diabetes.

SGLT2 inhibitors can be considered in treatment plans to improve cardiovascular outcomes in diabetic patients.

SGLT2 inhibitors may slow the progression of chronic kidney disease in high-risk individuals with type 2 diabetes.

SGLT2 inhibitors should be considered for patients at risk of chronic kidney disease.

Correlations between 3-day mean intakes for energy and six key nutrients were above 0.7 except for sodium intake.

High correlations suggest that MijnEetmeter can be a reliable tool for tracking most nutrients.

Having a normal body weight does not automatically imply preserved metabolic health.

Practitioners should assess metabolic health beyond just body weight.

There is evidence for the presence of metabolically unhealthy normal weight (MUHNW) and metabolically healthy obese (MHO) phenotypes.

Understanding these phenotypes can guide personalized treatment approaches.

GLP-1 receptor agonists (GLP-1RAs) are associated with accelerated facial aging and altered skin health.

Clinicians should be aware of the potential for accelerated facial aging in patients treated with GLP-1RAs.

The accelerated facial aging observed in GLP-1RA patients is multifactorial, involving loss of dermal and subcutaneous white adipose tissue.

Understanding the multifactorial nature of aging can guide treatment approaches for affected patients.

Treatment strategies targeting adipose-derived stem cell (ADSC) stimulation may mitigate facial aging effects from GLP-1RAs.

Clinicians may consider ADSC-targeted treatments to improve skin health in patients using GLP-1RAs.

The implementation of MBSAQIP and ERAS protocols has significantly improved the quality of care for all bariatric patients.

Healthcare providers should adopt MBSAQIP and ERAS protocols to enhance patient outcomes.